Sign in

CABR on Nasdaq

Caring Brands, Inc.

Caring Brands, Inc. is an American perfumes company that raised $1.8 million in 2024 (SEC Form D).1 It is headquartered in Fort Pierce, Florida.1 Its shares trade on Nasdaq under the symbol CABR.1

$1.32 up 0.02 (1.54%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 21, 2026.

Overview

Compare with Scientist Home Future Health Ltd, BONK, INC. or DSwiss Inc, or pick any stock.

  • TickerCABR on Nasdaq1
  • IndustryPerfumes, Cosmetics & Other Toilet Preparations1
  • HeadquartersFort Pierce, Florida1
  • Incorporated inNV3
  • Business address130 S Indian River Drive, Suite 202 Pbm# 1232, Fort Pierce, Fl 349503
  • Filer category, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

78% of total sales and growing at a compound annual growth rate of approximately 18%.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

55.6%Gross margin6
-140807.2%Operating margin6
-148948.8%Net margin6
-300.2%Return on equity6
0.03×Debt to equity6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue1¢$1.9K
  • Selling, general and admin99¢$147.7K

Out of $4.2K in revenue.6 The company lost money this year.

Financial statements

Net income6-$6.3M in 2025+314% since 2024
-$8.0M-$6.0M-$4.0M-$2.0M02024: -$1.5M-$1.5M20242025: -$6.3M-$6.3M2025+314%
Fiscal year202320242025
Revenue$4.2K6
Cost of revenue$1.9K6
Gross profit$2.3K6
Research and development$39.6K6$06
Selling, general and admin$147.7K6
Operating expenses$5.9M6
Operating income-$5.9M6
Income tax$06$06
Net income-$1.5M6-$6.3M6
Earnings per share-$0.466
Earnings per share (diluted)-$0.466
Shares (weighted, basic)13.6M shares6
Shares (weighted, diluted)13.6M shares6

Compare Caring Brands, Inc. with another company

What it owns

What Caring Brands, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.2M6 Dec 31, 2025$469.0K6 Dec 31, 2024+366.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$2.5M6 Dec 31, 2025
Finite-lived intangibles, gross$3.0M6 Dec 31, 2025$3.0M6 Dec 31, 20240%
Accumulated amortization-$450.0K6 Dec 31, 2025-$150.0K6 Dec 31, 2024−200.0%
Finite-lived intangibles, net$2.9M6 Dec 31, 2024

Inventory

ItemLatestA year beforeChange
Inventory, total$12.8K6 Dec 31, 2025$13.7K6 Dec 31, 2024−6.4%

Properties, in its own words

Currently, we do not own any real property. We currently lease office space at 130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950.

Item 2 of the 10-K filed Mar 31, 2026.5

Leadership

Who has led Caring Brands, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Glynn Wilson2025–now

Chief financial officer

  1. Tyler Thomas Moore2025–2026
  2. Brian Meadows2026–now
Board members and other officers (5)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Executive OfficerBRIAN JOHN named Apr 23, 202416

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Caring Brands, Inc. Florida4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Sep 22, 20268-K Entered a material agreement; Executive or director change17
  2. Sep 11, 20268-K Unregistered sale of shares; Regulation FD disclosure18
  3. Sep 10, 20268-K Entered a material agreement; Executive or director change19
  4. Sep 2, 20268-K Regulation FD disclosure20
  5. Sep 1, 20268-K Unregistered sale of shares; Other events21
  6. Aug 25, 20268-K Entered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed22
  7. Aug 6, 20268-K Other events23
  8. Jul 17, 20268-K Listing notice or transfer24
  9. Jul 16, 20268-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights25
  10. Jul 14, 20268-K Shareholder vote26
  11. Jun 1, 20268-K Regulation FD disclosure27
  12. May 29, 20268-K Other events28
  13. Nov 14, 2025New chief executive Glynn Wilson becomes CEO9

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202629

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

87 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 19 major events, 20 insider forms, 1 private raises, 43 other. The latest 20:

  1. Sep 30, 20264 EDGAR
  2. Sep 30, 20264 EDGAR
  3. Sep 30, 20264 EDGAR
  4. Sep 30, 20264 EDGAR
  5. Sep 22, 20268-K EDGAR
  6. Sep 17, 20263 EDGAR
  7. Sep 11, 20268-K EDGAR
  8. Sep 10, 20268-K EDGAR
  9. Sep 2, 20268-K EDGAR
  10. Sep 1, 20268-K EDGAR
  11. Aug 25, 20268-K EDGAR
  12. Aug 13, 202610-Q EDGAR
  13. Aug 6, 20268-K EDGAR
  14. Jul 28, 20264 EDGAR
  15. Jul 17, 20268-K EDGAR
  16. Jul 16, 20268-K EDGAR
  17. Jul 14, 20268-K EDGAR
  18. Jun 1, 2026DEFA14A EDGAR
  19. Jun 1, 20268-K EDGAR
  20. May 29, 20268-K EDGAR

The 87 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.8M 2024–2024
Money received by yearMoney received by year, 2024–2024: $1.8M in all. Private raises (Form D) $1.8M.$0$500K$1M$1.5M$2M2024 · Private raises (Form D): $1.8M2024
Figures by year
YearPrivate raises (Form D)Total
2024$1.8M$1.8M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Apr 16, 2024Raised $1.8 million in a private offering of equity16 Form D: $3 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Franklin Resources Inc35,970$44.6K0.0%New
Vanguard Capital Management LLC26,155$32.4K0.0%+8,904
Geode Capital Management, LLC24,936$30.9K0.0%−33,897
Susquehanna International Group, Llp20,771$25.8K0.0%New
XTX Topco Ltd18,484$22.9K0.0%−2,290
Jane Street Group, LLC15,647$19.4K0.0%−20,021
LPL Financial LLC10,000$12.4K0.0%New
UBS Group AG3,523$4.4K0.0%New
Tower Research Capital LLC (TRC)2,459$3.0K0.0%+1,981
Caitong International Asset Management Co., Ltd1$10.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Caring Brands, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCaring Brands, Inc.1
  • CIK0002020737
  • Employer ID (EIN)99-41039085
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company5
  • Incorporated inNevada5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2844 Perfumes, Cosmetics & Other Toilet Preparations1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address130 S Indian River Drive, Suite 202 Pbm# 1232, Fort Pierce, FL 349501
  • Phone561-896-76161
  • Shares outstanding10,368,226 as of Aug 13, 20268
  • Public float$4.0M as of Jun 30, 20255
  • AuditorM&K CPAS, PLLC, The Woodlands, Texas PCAOB ID 2738; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceApr 23, 20241
  • Filings87 in all: 8-K (19), 4 (13), UPLOAD (9), CORRESP (8), 3 (7), S-1/A (4), 10-Q (3), DRS/A (3)1
    All 22 form types

    DRSLTR (3), S-1 (3), 424B4 (2), DRS (2), EFFECT (2), 10-K (1), 8-A12B (1), CERT (1), D (1), DEF 14A (1), DEFA14A (1), PRE 14A (1), RW (1), S-8 (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) May 27, 2026
    Latest 8-K (8-K) Sep 22, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareCABRNASDAQ

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Caring Brands, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 59 risks under these headings, as written.5

  • We may not be successful in preventing the material adverse effects that any of the following risks and uncertainties may cause. These potential risks and uncertainties may not be a complete list of the risks and uncertainties facing us. There may be additional risks and uncertainties that we are presently unaware of, or presently consider immaterial, that may become material in the future and have a material adverse effect on us. You could lose all or a significant portion of your investment due to any of these risks and uncertainties.
  • Risks Related to Our Business
  • Caring Brands has a limited operating history, which makes it difficult to accurately evaluate our business prospects.
  • Our financial situation creates doubt whether we will continue as a going concern.
  • If we are unable to keep up with rapid technological changes, our products may become obsolete.
  • We may not have adequate capital to fund our business.
  • Competition could adversely affect our business.
  • We may not be able to successfully compete against companies with substantially greater resources.
  • If we are unable to develop and maintain our brand and reputation for our product offerings, our business and prospects could be materially harmed.
  • We depend heavily on key personnel, and turnover of key senior management could harm our business.
  • We are subject to government regulation, and unfavorable changes could substantially harm our business and results of operations.
  • Our products may not meet health and safety standards or could become contaminated.
The other 48 risks
  • The sale of our products involves product liability and related risks that could expose us to significant insurance and loss expenses.
  • The success of our business will depend upon our ability to create and expand our brand awareness.
  • We must develop and introduce new products to succeed.
  • We cannot assure you that we will develop additional products in the future.
  • Adverse publicity associated with our products or ingredients, or those of similar companies, could adversely affect our sales and revenue.
  • We do not have and may never have any products on the market that have been approved by the FDA for the treatment of disease. The labelling of Photocil was registered with the FDA and is an OTC product. The labelling of Photocil and Minoxidil Booster were approved by the Indian regulatory authorities. Our business is highly dependent upon complying with regulations for cosmetic and OTC product from various U.S. and international governmental agencies.
  • We have limited experience in completing regulatory filings and any delays in regulatory filings could materially affect our financial condition.
  • If serious adverse or undesirable side effects are identified during the development of our product candidates, we may abandon or limit our development or commercialization of such product candidates.
  • If we experience delays or difficulties in the enrollment of subjects to our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented, which could materially affect our financial condition.
  • If we or our licensees, development collaborators, or suppliers are unable to manufacture our products in sufficient quantities or at defined quality specifications, or are unable to obtain regulatory approvals for the manufacturing facility, we may be unable to develop or meet demand for our products and lose time to market and potential revenues.
  • It is uncertain whether product liability insurance will be adequate to address product liability claims, or that insurance against such claims will be affordable or available on acceptable terms in the future.
  • If the market opportunities for our current and potential future drug candidates are smaller than we believe they are, our ability to generate product revenues may be adversely affected and our business may suffer.
  • If we are unable to establish relationships with licensees or collaborators to carry out sales, marketing, and distribution functions or to create effective marketing, sales, and distribution capabilities, we will be unable to market our products successfully.
  • Our ability to market our products in the United States depends on their regulatory classification and compliance with applicable regulations.
  • Commercial success of our OTC/Cosmetic product candidates will depend on the acceptance of these products by physicians, payers, and patients.
  • If we obtain FDA approval for any of our product candidates, we will be subject to various federal and state fraud and abuse laws; these laws may impact, among other things, our proposed sales, marketing and education programs. Fraud and abuse laws are expected to increase in breadth and in detail, which will likely increase our operating costs and the complexity of our programs to insure compliance with such enhanced laws.
  • If our operations are found to be in violation of any of the federal and state fraud and abuse laws or any other governmental regulations that apply to us, we may be subject to criminal actions and significant civil monetary penalties, which would adversely affect our ability to operate our business and our results of operations.
  • Natural disasters and other events beyond our control could materially adversely affect us.
  • We may not meet our product development and commercialization milestones.
  • Our operations in international markets involve inherent risks that we may not be able to control.
  • Risks Relating to the Separation
  • We may be unable to achieve some or all of the benefits that we expect to achieve from the Separation.
  • We have a limited operating history as a publicly traded company, and our historical financial information is not necessarily representative of the results we would have achieved as a publicly traded company and may not be a reliable indicator of our future results.
  • We may not be able to access the credit and capital markets at the times and in the amounts needed on acceptable terms.
  • The insurance that we maintain may not fully cover all potential exposures.
  • Some of our directors and executive officers own Safety Shot common stock or options to acquire Safety Shot common stock and hold positions with Safety Shot, which could cause conflicts of interest, or the appearance of conflicts of interest, that result in our not acting on opportunities we otherwise may have.
  • Risks Related to our Financial Position and Capital Needs
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or other assets.
  • Our potential for rapid growth and our entry into new markets make it difficult for us to evaluate our current and future business prospects, and we may be unable to effectively manage any growth associated with these new markets, which may increase the risk of your investment and could harm our business, financial condition, results of operations and cash flow.
  • Changes in tax laws and unanticipated tax liabilities could adversely affect our effective income tax rate and ability to achieve profitability.
  • Risks Related to our Intellectual Property
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
  • Any inability to protect our intellectual property rights could reduce the value of our products and brands, which could adversely affect our financial condition, results of operations and business.
  • The intellectual property behind our products may include unpublished know-how as well as existing and pending intellectual property protection. All intellectual property protection eventually expires, and unpublished know-how is dependent on key individuals.
  • If we are not able to adequately protect our intellectual property, then we may not be able to compete effectively, and we may not be profitable.
  • Risks Related to Ownership of Our Securities
  • We are an “emerging growth company” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.
  • The requirements of being a public company may strain our resources and distract our management, which could make it difficult to manage our business, particularly after we are no longer an “emerging growth company.”
  • Our management has limited experience in managing the day-to-day operations of a public company and, as a result, we may incur additional expenses associated with the management of our Company.
  • Compliance with changing corporate governance regulations and public disclosures may result in additional risks and exposures.
  • Certain of our stockholders hold a significant percentage of our outstanding voting securities, which could reduce the ability of minority stockholders to effect certain corporate actions.
  • If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price could decline.
  • Our issuance of additional common stock or preferred stock may cause our common stock price to decline, which may negatively impact your investment.
  • Our common stock may become subject to the SEC’s penny stock rules and accordingly, broker-dealers may experience difficulty in completing customer transactions and trading activity in our securities may be adversely affected.
  • If we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and have an adverse effect on the value of our securities.
  • As an emerging growth company, our auditor will not be required to attest to the effectiveness of our internal controls.
  • Risks Related to Ownership of Our Common Stock
  • The market price of our securities may be volatile, which could cause the value of your investment to decline.
  • We may not be able to satisfy listing requirements of the NASDAQ or obtain or maintain a listing of our common stock on the NASDAQ.
  • We do not intend to pay dividends for the foreseeable future.
  • Sales of a substantial number of shares of our Common Stock in the public market could cause our stock price to fall.
  • Anti-takeover provisions in the Company’s charter and bylaws may prevent or frustrate attempts by stockholders to change the board of directors or current management and could make a third-party acquisition of the Company difficult.
  • We have identified material weaknesses in our internal controls over financial reporting. If we are unable to remediate these material weaknesses, if management identifies additional material weaknesses in the future or if we otherwise fail to maintain effective internal controls over financial reporting, we may not be able to accurately or timely report our financial position or results of operations, which may adversely affect our business and stock price or cause our access to the capital markets to be impaired.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently a party to any legal or administrative proceedings. Our current officers and directors have not been convicted in a criminal proceeding nor have they been permanently or temporarily enjoined, barred, suspended or otherwise limited from involvement in any type of business, securities or banking activities.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
    Yahoo FinanceCABR quote
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
    SEC EDGAROther events
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29